Tango Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 11, 2026
TNGX$22.74+5.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| June 30, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $345,558 | $112,279 |
| Marketable securities | 668,432 | 230,859 |
| Restricted cash | — | 428 |
| Prepaid expenses and other current assets | 17,681 | 10,190 |
| Total current assets | 1,031,671 | 353,756 |
| Property and equipment, net | 6,094 | 6,868 |
| Operating lease right-of-use assets | 33,664 | 35,624 |
| Restricted cash, net of current portion | 2,139 | 2,139 |
| Other assets | 312 | 303 |
| Total assets | $1,073,880 | $398,690 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $1,810 | $1,182 |
| Accrued expenses and other current liabilities | 15,546 | 17,759 |
| Operating lease liabilities | 2,943 | 2,738 |
| Total current liabilities | 20,299 | 21,679 |
| Operating lease liabilities, net of current portion | 29,049 | 30,832 |
| Total liabilities | 49,348 | 52,511 |
| Commitments and contingencies (Note 7) | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | — | — |
| Stockholders' equity: | ||
| Common stock, $0.001 par value; 400,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively; 168,380,091 and 135,940,454 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 168 | 136 |
| Additional paid-in capital | 1,729,004 | 948,971 |
| Accumulated other comprehensive (loss) income | (633) | 224 |
| Accumulated deficit | (704,007) | (603,152) |
| Total stockholders’ equity | 1,024,532 | 346,179 |
| Total liabilities and stockholders’ equity | $1,073,880 | $398,690 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.